[±Ù°Å±â¹Ý ÀÓ»óÁú¹® ´äº¯]
°£ ÀÌ½Ä ¼ö¼úÀ» ¹ÞÀº °£¼¼Æ÷¾ÏÁ¾(Hepatocellular Carcinoma)ȯÀÚ¿¡°Ô Everolimus Åõ¿©È¿°ú
ÀÓ»óÁú¹®
|
°£¼¼Æ÷¾ÏÁ¾(Hepatocellular Carcinoma, HCC) ȯÀÚ°¡ °£À̽Ä(Living donor liver transplantation, LDLT) ¼ö¼úÀ» ¹ÞÀº ÈÄ, ¸é¿ª¾ï¾ÐÁ¦·Î¼ Everolimus (EVR)Åõ¿©°¡ Àç¹ß °¨¼Ò¿¡ È¿°úÀûÀԴϱî?
|
±Ù°Å±â¹Ý ´äº¯
|
°£À̽ÄÀ» ¹ÞÀº HCC ȯÀÚ¿¡°Ô Ãʱâ EVR »ç¿ëÀº Tacrolimus (TAC) ´Üµ¶Ä¡·á±º°ú ºñ±³ÇÏ¿© HCC ȯÀÚÀÇ °£¼¼Æ÷ Àç¹ßÀ²À» °¨¼Ò½Ãŵ´Ï´Ù.
|
¼ÁöÁ¤º¸
|
Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors (2017) DOI: https://doi.org/10.14701/ahbps.2017.21.4.205
|
¿¬±¸¸ñÀû
|
HCC ȯÀÚ°¡ LDLT ¼ö¼ú ÈÄ, ¸é¿ª¾ï¾ÐÁ¦ EVR Åõ¿© È¿°ú
|
¿¬±¸¼³°è
|
ºñ¹«ÀÛÀ§ ½ÃÇè´ëÁ¶±º(Non-randomized controlled trial, NRCT)
|
¿¬±¸´ë»ó
|
LDLT ¼ö¼úÀ» ¹ÞÀº HCC ȯÀÚ 250¸í
|
½ÃÇ豺 ÁßÀç
|
°£¼¼Æ÷¾ÏÁ¾(HCC) ȯÀÚ LDLT ÈÄ EVR + TAC Åõ¿©±º
|
´ëÁ¶±º ÁßÀç
|
°£¼¼Æ÷¾ÏÁ¾(HCC) ȯÀÚ LDLT ÈÄ TAC ´Üµ¶ Åõ¿©±º
|
Æò°¡ÁöÇ¥
|
°£¼¼Æ÷¾ÏÁ¾(HCC) Àç¹ß·ü (HCC recurrence rates)
|
ÁÖ¿ä °á°ú
|
- Ãʱ⠰£ ÀÌ½Ä È¯ÀÚ¿¡¼ÀÇ EVR »ç¿ëÀº HCC ȯÀÚÀÇ °£¼¼Æ÷ Àç¹ßÀ²À» UCSF ±âÁØ¿¡¼ °¨¼Ò½Ãŵ´Ï´Ù. A ±ºÀÇ °æ¿ì EVRÀÇ Æò±Õ ÃÖÀú ³óµµ´Â 3.47 ± 1.53 ng / ml (¹üÀ§, 1.5-11.2)À̾ú°í ÀÏÀÏ Åõ¿©·®Àº 1.00 ± 0.25 mg / ÀÏ À̾ú´Ù.
- A ±º°ú B ±ºÀÇ Æò±Õ TAC ·¹º§Àº °¢°¢ 6.97 ± 3.98 ng / ml (2.50 ~ 11.28 ng / ml)¿Í 6.93 ± 2.58 (range, 2-16.30)À̾ú´Ù.
- A ±º ȯÀÚÀÇ 1 ³â, 3 ³â, 4 ³â »ýÁ¸À²Àº °¢°¢ 94.95 %, 86.48 % ¹× 86.48 % ¿´°í, B ±ºÀÇ °æ¿ì 82.75 %, 68.96 %, 62.06 % ·Î º¸°í µÇ¾ú´Ù(p=0.0217).
|
±Ù°Å¼öÁØ
|
Moderate
|
ÀÛ¼ºÀÚ
|
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)
Copyright © 2015. Medical Research Information Center (MedRIC) Editors
|